Deerfield Management Company L.P. Series C Invests $464,000 in West Pharmaceutical Services, Inc. (NYSE:WST)

Deerfield Management Company L.P. Series C bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,409 shares of the medical instruments supplier’s stock, valued at approximately $464,000.

Other large investors also recently made changes to their positions in the company. APG Asset Management US Inc. bought a new position in West Pharmaceutical Services during the 4th quarter worth $88,227,000. LGT Group Foundation acquired a new position in shares of West Pharmaceutical Services in the second quarter valued at about $68,854,000. Liontrust Investment Partners LLP bought a new position in West Pharmaceutical Services during the second quarter worth about $64,196,000. Findlay Park Partners LLP raised its stake in West Pharmaceutical Services by 30.6% in the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock worth $236,281,000 after purchasing an additional 139,800 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new stake in West Pharmaceutical Services in the 1st quarter valued at about $47,381,000. Institutional investors own 93.90% of the company’s stock.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at approximately $443,400. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.53% of the stock is owned by insiders.

West Pharmaceutical Services Stock Up 1.3 %

Shares of WST opened at $311.00 on Friday. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The firm’s 50 day moving average is $301.92 and its 200-day moving average is $335.70. The stock has a market capitalization of $22.56 billion, a PE ratio of 41.03, a P/E/G ratio of 11.04 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s revenue was down 6.9% on a year-over-year basis. During the same quarter last year, the business earned $2.11 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.